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Abstract This study was a retrospective chart review per-
formed to examine and describe physician practice patterns
in managing attention deficit/hyperactivity disorder
(ADHD) across Europe. Physicians treating ADHD in the
UK, France, Germany, Italy, the Netherlands and Spain were
recruited. Each physician abstracted medical records of five
patients (aged 6–17 years at time of review) with a docu-
mented diagnosis of ADHD made between January 2004
and June 2007. Data provided by the physician via the
abstraction included (a) physician characteristics, (b) patient
characteristics, (c) ADHD diagnosis and (d) ADHD out-
comes (adherence, symptom control and satisfaction). A
total of 779 patients met study inclusion criteria. In the
overall population, patients’ mean (SD) age at time of diag-
nosis was 8.9 (2.6) years. The predominant treatment choice
was long-acting methylphenidate, which was prescribed to
more than 56 % of patients. According to physicians, only
30.8 % of patients showed ‘complete symptom control’ on
current treatment and only 31.8 % of physicians reported
being ‘very satisfied’ with their patients’ current treatment.
Physicians’ assessments of complete symptom control and
physician satisfaction with treatment were low, indicating
unmet needs with current ADHD management in Europe.
Keywords Attention deficit/hyperactivity disorder .
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Abbreviations
ADHD Attention deficit/hyperactivity disorder
BT Behavioural therapy
Connors ADHD Connors Test
DSM-IV Diagnostic and Statistical Manual
of Mental Disorders 4th edn
ICD-9/ICD-10 International Classification of Diseases
9th and 10th Revision
IOWA Inattention/Overactivity With
Aggression screening tool
SNAP-IV Swanson, Nolan and Pelham IV
Rating Scale
Introduction
Attention deficit/hyperactivity disorder (ADHD) affects as
many as 3 to 9 % of children worldwide [15, 19] and is
associated with significant and wide-ranging impairments.
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ADHD is one of the most common psychiatric disorders in
childhood and is characterized by developmentally inappro-
priate levels of inattention, hyperactivity and/or impulsivity
[2]. Children with ADHD struggle in the areas of academic
functioning, self-esteem and interpersonal relationships [1,
13, 14], and they are at higher risk for mental health comor-
bidities such as mood disorders and substance use disorders
[4, 5, 8, 22]. Studies have shown that families of children
with ADHD experience considerable emotional and finan-
cial stressors [10, 12, 23], and ADHD has also been shown
to negatively impact the health-related quality of life for
both children and adults [9]. Taken together, these negative
short- and long-term outcomes of ADHD on patients and
families make it a public health concern and affirm the need
for effective treatment [15].
According to European guidelines, the diagnosis and
management of ADHD consists of nonpharmacological
options, including behavioural therapy (BT), and pharma-
cological options, including stimulants (long- and short-
acting methylphenidates and amphetamines) and nonstimu-
lants [15, 24]. However, the availability of and access to
treatments vary across countries. Although much is known
about the efficacy and safety of individual ADHD treatment
options via randomized, controlled clinical trials, real-world
treatment and utilization patterns of current ADHD thera-
pies as well as physician practice patterns in the manage-
ment of ADHD across European countries have not been
studied extensively. Cultural beliefs and differences across
countries contribute to the real-world variation regarding
how ADHD is managed. To better understand current
ADHD management in ‘the real world’ across Europe, it is
important to understand how physicians in different
countries diagnose and manage ADHD. It is also important
to understand physician’s perceptions on how currently
available medications to treat ADHD are working to manage
the condition. The purpose of this retrospective chart review
was to descriptively illustrate variation in physician practice
patterns in the management of ADHD in various Western
European countries.
Methods
This study was designed as a retrospective review of patient
medical records by their treating physicians (Fig. 1). In
2009, paediatricians, neuropaediatricians, child and/or ado-
lescent psychiatrists and paediatric neurologists who treated
patients with ADHD were identified from a database of
healthcare providers in six countries in Western Europe:
the UK, France, Germany, Italy, the Netherlands and Spain.
Participating physicians were identified through the follow-
ing sources: (a) physician directories maintained by local
European medical associations and (b) local physician
telephone directories. Overall, no formal sampling proce-
dure was employed for physician recruitment; however,
physicians with ADHD expertise or prior positive working
relationships with the fieldwork company were initially
selected to be contacted for study participation.
Physicians were contacted by either email or phone calls
to assess physician eligibility and interest in participating in
the study. If eligible physicians indicated interest, they were
directed to complete a web-based screening questionnaire.
Physicians were screened as eligible for inclusion in the
study if they were engaged in clinical practice for between
3 and 30 years, managed the treatment of at least five
ADHD patients (aged 6–17 years) per month and were
responsible for making ADHD treatment decisions.
Physicians were required to identify the most recent
ADHD patients (up to a maximum of five patients aged 6–
17 years) that they had seen at the time of the review. In
order for patients to be included in the study, they should
have had a documented diagnosis of ADHD between Janu-
ary 2004 and June 2007 and have had at least 2 years of
follow-up post-diagnosis. Patients were also required to
have received either pharmacological treatment or BT fol-
lowing the ADHD diagnosis. Patient charts were excluded if
there was evidence of enrolment in a randomized clinical
trial. No other specific sampling strategies were employed.
Physicians abstracted patient chart data, entered the data
into an electronic web-based form and then translated it into
the local language. Instructions for completing the chart ab-
straction were provided on the web-based form. The data
collection tool was designed in such a way that physicians
were not able to skip any questions; however, if certain
information was not available in the patients’ chart, physicians
could select a ‘don’t know’ option. Wording for key questions
regarding satisfaction, symptom control and adherence to the
treatment regimen has been included in the Appendix. Each
chart abstraction form was estimated to take 15 to 30 min to
complete. All data gathered were de-identified and made
completely anonymous. As no identifying patient information
was collected, physicians did not have to obtain permission
from patients before abstracting charts. Physicians were nom-
inally compensated for their time.
Fig. 1 Study design
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Variables for assessment
Both physician characteristics and patient characteristics
were collected. The following patient characteristics were
collected from the chart: age at diagnosis and at start of
treatment, gender, ethnicity, insurance status, education lev-
el, reasons for seeking evaluation, comorbidities at diagno-
sis and the level of patient engagement and family
involvement with the condition and its treatment on a ten-
point scale where 1 represents ‘not engaged/involved at all’
and 10 represents ‘strongly engaged/involved’. Other
ADHD-related information collected included ADHD diag-
nostic criteria utilized, ADHD treatment goals, ADHD
symptom presentation and levels of impairment at the time
of ADHD diagnosis on a ten-point scale where 1 repre-
sented ‘no impairment’ and 10 represented ‘high level of
impairment’ (from 2004 to 2007). Also, treatment modali-
ties were collected starting from the time of chart abstraction
and going backwards up to five previous ADHD treatments.
Data collected on treatment modalities included dose, pre-
scription date and reason for changing dose and/or therapy.
A switch from one treatment modality to another or a
discontinuation of treatment was considered as new treat-
ment. Dose changes for the same medication were not
considered as new treatment. Data on treatments adminis-
tered in other clinics or those that exceeded the last five
treatments were not documented.
Data on adherence to current and previous ADHD treat-
ments were also collected. Physicians were asked to report on
the patient’s ADHD symptom control (‘completely’, ‘moder-
ately’, ‘poorly’ or ‘not controlled’) and their satisfaction level
(‘very satisfied’, ‘moderately satisfied’, ‘neither satisfied nor
dissatisfied’, ‘moderately dissatisfied’ or ‘very dissatisfied’)
with treatment at time of chart abstraction.
Variable transformations
Associations between patient characteristics and outcomes
were examined using a binary outcome definition for
adherence, physician perception of symptom control and
physician satisfaction (all with current therapy at time of
review) to simplify the analysis and its interpretation.
Physician-estimated adherence to treatment was defined
as >80 % adherence during weekdays and >50 % adher-
ence during weekends and holidays in accordance with the
literature characterizing the medication possession ratio
[20] and its use in assessing ADHD medication adherence
[3]. The four levels of symptom control were dichotomized
to ‘completely controlled’ vs ‘moderately’, ‘poorly’ or ‘not
controlled’. The five levels of physician satisfaction were
dichotomized to ‘very satisfied’ vs ‘moderately satisfied’,
‘neither satisfied nor dissatisfied’, ‘moderately dissatisfied’
or ‘very dissatisfied’.
Statistical analysis
All study variables were summarized descriptively. Contin-
uous variables were summarized and expressed in mean
values, medians, ranges and standard deviations. Categori-
cal variables were summarized in the form of proportion and
frequency distributions. Summary statistics are provided by
country for physician, patient and treatment characteristics
and for diagnosis criteria used.
The significance (p<0.05) of the associations was tested
using Fisher’s exact or t-tests for dichotomous and continu-
ous variables, respectively. Odds ratios were reported for
dichotomous values and mean values were reported for
continuous variables.
All data were analysed using statistical software (SAS




A total of 340 physicians reviewed and abstracted charts for 779
patients. On average, physicians were engaged in clinical prac-
tice for 15 years (range 3 to 30 years). Each physician managed
approximately 20 patients aged 6 to 12 years and 15 patients
aged 13 to 17 years. Medical specialties are listed in Table 1.
Patient characteristics
Patient demographics
Patient demographics are presented in Table 2. Patient mean
(SD) age at diagnosis was 8.9 (2.6) years old, which was similar
across countries. The mean (SD) patient age at the start of chart
abstraction was 12.1 (2.6) years, with little variation across
countries. The majority of the patients (77.5 % [604/779]) were
male and Caucasian (85.8 % [557/649]). In France, the ethnic-
ity of the patient was not allowed to be reported; therefore, the
ethnicity data are based on a sample of 649 instead of 779
patients. Approximately 49 % (384/779) of patients had one to
three comorbidities at the time of diagnosis (Fig. 2). The most
commonly reported comorbidities were behavioural disorders
(59.3 % [462/779]), learning disabilities (47.4 % [369/779]),
anxiety (35.7 % [278/779]), aggression (35.3 % [275/779]) and
oppositional defiant disorder (34.3 % [267/779]).
ADHD diagnosis
Feedback from teachers at school was the most common
reason for seeking ADHD evaluations (78.3 % [610/779])
across all countries. Challenges raised by parents/family
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were also a common reason for seeking evaluation among
63.8 % (497/779).
Across all countries, the commonly used diagnostic criteria
included the Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM-IV) (55.7 % [434/779]), and
International Classification of Diseases, Revision 9 or 10
(ICD-9/ICD-10) (46.3 % [361/779]). ADHD Connors Test
(49.4 % [385/779]) was also commonly used, though physi-
cians may have usedmore than one set of diagnostic criteria to
make an ADHD diagnosis. As presented in Table 1, within
each country the diagnostic criteria utilized varied based on
physician specialty.
ADHD symptoms and impairment levels at diagnosis
The most common symptoms at diagnosis were the core symp-
toms of ADHD (inattention, impulsivity and hyperactivity) as
well as impairments with school performance (Fig. 3).
Table 1 ADHD diagnostic criteria and scales utilized by specialty for each country (physicians could select more than one diagnostic criterion
utilized at diagnosis)
Country Specialty (n) Patients (n) ADHD diagnostic criteria and scales, n (%)
DSM-IV ICD-9/ICD-10 SNAP-IV Connors IOWA Other
France Paediatrician (1) 5 5 (100.0) 0 0 5 (100.0) 0 0
Neuropaediatrician (2) 7 6 (85.7) 6 (85.7) 5 (71.4) 2 (28.6) 0 0
Neuropsychiatrist (1) 2 2 (100) 0 0 0 0 0
Psychiatrist (26) 60 39 (65.0) 31 (51.7) 7 (11.7) 25 (41.7) 1 (1.7) 0
Paediatric/adolescent
psychiatrist (18)
53 35 (66.0) 26 (49.1) 1 (1.9) 31 (58.5) 0 0
Neurologist (2) 3 3 (100) 0 0 1 (33.3) 0 0
Total (50) 130 90 (69.2) 63 (48.5) 13 (10.0) 64 (49.2) 1 (0.8) 0
Germany Paediatrician (24) 70 17 (24.3) 56 (80.0) 4 (5.7) 47 (67.1) 4 (5.7) 0
Neuropaediatrician (9) 26 6 (23.1) 25 (96.2) 1 (3.8) 22 (84.6) 0 0
Psychiatrist (12) 35 8 (22.9) 31 (88.6) 1 (2.9) 28 (80.0) 0 0
Paediatric/adolescent
psychiatrist (7)
20 0 20 (100.0) 1 (5.0) 17 (85.0) 1 (5.0) 0
Total (52) 151 31 (20.5) 132 (87.4) 7 (4.6) 114 (75.5) 5 (3.3) 0
Italy Paediatrician (28) 56 41 (73.2) 20 (35.7) 11 (19.6) 18 (32.1) 3 (5.4) 0
Neuropaediatrician (38) 74 50 (67.6) 29 (39.2) 18 (24.3) 21 (28.4) 5 (6.8) 0
Neuropsychiatrist (8) 14 10 (71.4) 5 (35.7) 0 4 (28.6) 0 0
Total (74) 144 101 (70.1) 54 (37.5) 29 (20.1) 43 (29.9) 8 (5.6) 0
Netherlands Paediatrician (30) 37 29 (78.4) 2 (5.4) 0 9 (24.3) 1 (2.7) 0
Neuropsychiatrist (1) 1 0 0 0 0 0 0
Psychiatrist (9) 12 12 (100.0) 0 0 4 (33.3) 0 0
Paediatric/adolescent
psychiatrist (16)
24 19 (79.2) 1 (4.2) 2 (8.3) 9 (37.5) 0 0
Total (56) 74 60 (81.1) 3 (4.1) 2 (2.7) 22 (29.7) 1 (1.4) 0
Spain Paediatrician (21) 60 50 (83.3) 14 (23.3) 16 (26.7) 13 (21.7) 5 (8.3) 0
Psychiatrist (15) 40 28 (70.0) 15 (37.5) 4 (10.0) 13 (32.5) 2 (5.0) 0
Paediatric/adolescent
psychiatrist (14)
34 28 (82.4) 15 (44.1) 3 (8.8) 15 (44.1) 3 (8.8) 0
Total (50) 134 106 (79.1) 44 (32.8) 23 (17.2) 41 (30.6) 10 (7.5) 0
UK Paediatrician (23) 57 20 (35.1) 11 (19.3) 0 42 (73.7) 3 (5.3) 20 (35.1)
Neuropaediatrician (2) 6 3 (50.0) 6 (100.0) 0 6 (100.0) 0 0
Psychiatrist (7) 18 7 (38.9) 11 (61.1) 4 (22.2) 6 (33.3) 0 9 (50.0)
Paediatric/adolescent
psychiatrist (26)
65 16 (24.6) 37 (56.9) 2 (3.1) 47 (72.3) 1 (1.5) 9 (13.8)
Total (58) 146 46 (31.5) 65 (44.5) 6 (4.1) 101 (69.2) 4 (2.7) 38 (26.0)
Total EU 779 434 (55.7) 361 (46.3) 80 (10.3) 385 (49.4) 29 (3.7) 38 (4.9)
n number of physician responses, ADHD attention deficit/hyperactivity disorder, DSM-IV Diagnostic and Statistical Manual of Mental Disorders,
4th edn, ICD-9/ICD-10 International Classification of Diseases, Revision 9 or Revision 10, SNAP-IV Swanson, Nolan and Pelham Rating Scale,
Version IV, Connors ADHD Connors Test, IOWA Inattention/Overactivity With Aggression screening tool
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Approximately 44 % (339/779) of patients were reported as
having all three core symptoms at the time of diagnosis (Fig. 3).
Furthermore, the majority of patients (63.7 % [496/779]) had
three or more additional symptoms at diagnosis. More than a
third of the patients exhibited anger, irritability and inappropri-
ate behaviours. At the time of diagnosis, most physicians
reported the level of impairment in inattention (67.9 %
[529/779]), impulsivity (53.0 % [413/779]), hyperactivity
(57.3 % [446/779]) and challenges in school (66.1 %
[515/779]) as 8 or above on a ten-point scale. Most patients
showed evidence of impairment both at school (91.1 %
[710/779]) and at home (81.4 % [634/779]).
ADHD treatment
ADHD treatment goals
At diagnosis, most physicians across all six countries indicated
(based on the provided choices) that a goal of ADHD treatment
was to improve attention and functioning at school or work for
Table 2 Demographics for patients aged 17 years and younger
France Germany Italy Netherlands Spain UK Total (Europe)
Number of patients 130 151 144 74 134 146 779
Gender, n (%)
Male 111 (85.4) 113 (74.8) 108 (75.0) 57 (77.0) 97 (72.4) 118 (80.8) 604 (77.5)
Female 19 (14.6) 38 (25.2) 36 (25.0) 17 (23.0) 37 (27.6) 28 (19.2) 175 (22.5)
Age at ADHD diagnosis
Mean (SD) 9.1 (2.5) 8.4 (2.1) 8.7 (2.9) 8.6 (2.6) 9.0 (2.3) 9.3 (2.8) 8.9 (2.6)
Median 9 8 8 9 9 9 9
Range (min, max) 3, 14 2, 15 4, 14 4, 15 3, 15 4, 15 2, 15
Age at chart abstraction
Mean (SD) 12.4 (2.6) 11.8 (2.3) 11.8 (2.8) 11.7 (2.5) 12.1 (2.5) 12.7 (2.7) 12.1 (2.6)
Median 12 12 11 12 12 13 12
Range (min, max) 6, 17 6, 17 7, 17 7, 17 7, 17 6, 17 6, 17
Patient currently in school, n (%)
Yes 109 (83.8) 144 (95.4) 135 (93.8) 72 (97.3) 123 (91.8) 126 (86.3) 709 (91.0)
No 15 (11.5) 5 (3.3) 9 (6.3) 2 (2.7) 10 (7.5) 16 (11.0) 57 (7.3)
Don't know 6 (4.6) 2 (1.3) 0 (0.0) 0 (0.0) 1 (0.7) 4 (2.7) 13 (1.7)
Private health insurance, n (%)
Yes 85 (65.4) 22 (14.6) 8 (5.6) 74 (100) 20 (14.9) 4 (2.7) 213 (27.3)
No 24 (18.5) 129 (85.4) 99 (68.8) 0 (0.0) 90 (67.2) 136 (93.2) 478 (61.4)
Don't know 21 (16.2) 0 (0.0) 37 (25.7) 0 (0.0) 24 (17.9) 6 (4.1) 88 (11.3)
SD standard deviation, min minimum, max maximum, ADHD attention deficit/hyperactivity disorder
Fig. 2 Number and type of
comorbidities at time of ADHD
diagnosis, all countries
(n=779). Note that physicians
can select more than one
comorbidity at diagnosis
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their patients (78.1 % [609/779]; Fig. 4). Additional therapeutic
goals were strongly aligned with controlling the other core
ADHD symptoms of hyperactivity (60.3 % [470/779])
and impulsivity (60.5 % [471/779]). Overall, the physicians
stated that they wanted control of all three core symptoms for
38.1 % (297/779) of their patients. Apart from core symptom-
related goals, the next most commonly indicated goals of
treatment were to improve behaviour (62.0 % [483/779]), fam-
ily relationships (51.4 % [400/779]) and relationship building
(42.5 % [331/779]).
Fig. 3 Symptoms and
impairment levels at diagnosis,
all countries (n=779). Note that
physicians can select more than
one symptom or impairment at
diagnosis. Horizontal bars and
data reflect the mean level of
impairment for that symptom at
diagnosis
Fig. 4 Therapeutic goals of
ADHD treatment at the time of
diagnosis for chart review
patients (>1 %), all countries
(n=779). Note that physicians
can select more than one
therapeutic goal of ADHD
treatment at time of diagnosis
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ADHD treatments utilized and treatment patterns
At the time of chart abstraction, 49.6 % (386/779) were on
their first ADHD treatment regimen (either drug or nondrug),
37.9 % (295/779) had one previous line of therapy and the
remaining 12.6 % (98/779) of patients received two or more
previous lines of therapy (Table 3). Germany had the most
number of patients with three or more total lines of therapy
(19.9 % [29/151]). Approximately 80 % of patients had
≤0.5 years between ADHD diagnosis and the initiation of
treatment.
Overall, 34.5 % (269/779) were treated with a combina-
tion of pharmacotherapy and BT, whereas 48.0 % (374/779)
of patients were undergoing treatment with pharmacothera-
py only and 11.6 % (90/779) with BT only (Table 3). A
small percentage of patients (5.9 % [46/779]) did not receive
any treatment at the time chart abstraction was completed.
Across all countries, excluding Italy where long-acting
methylphenidates are not approved for use, long-acting
methylphenidate was the predominant treatment choice
(among 55.8 % of patients) either as monotherapy or in
combination. Overall, short-acting methylphenidates
(25.1 % of patients) and atomoxetine (13.5 % of patients)
were the next most commonly used treatments (Table 3).
Association between key predictor variables and outcomes
Overall, 71.4 % of patients with ADHD were estimated by
physicians to have high rates of adherence (>80 % weekdays
and >50%weekends). Adherence was estimated to be highest
in patients receiving combination medication therapy
(80.0 %) and lowest for patients receiving BT only (12.2 %).
However, according to physician judgement, only 30.8 % of
patients showed ‘complete symptom control’. Symptom con-
trol was highest for patients receiving long-acting methylphe-
nidate (36.2 %) and lowest for patients receiving BT only
(15.6 %). Only 31.8 % of physicians were ‘very satisfied’
with their patients’ ADHD treatment at the time of chart
abstraction. Highest physician satisfaction was reported for
patients receiving medication combination therapy (38.8 %)
and lowest satisfaction was reported for patients receiving BT
only (14.4 %).
Table 3 ADHD treatment utilization and patterns
France Germany Italy Netherlands Spain UK Total (Europe)
N % N % N % N % N % N % N %
Total number of patients (N) 130 151 144 74 134 146 779
Lines of treatment
One 85 65.4 77 51.0 81 56.3 46 62.2 69 51.5 64 43.8 386 49.6
Two 37 28.5 45 29.8 60 41.7 19 25.7 48 35.8 55 37.7 295 37.9
Three 7 5.4 24 15.9 3 2.1 7 9.5 15 11.2 17 11.6 73 9.4
Four 1 0.8 3 2.0 0 0.0 1 1.4 1 0.8 7 4.8 18 2.3
Five or more 0 0.0 2 1.3 0 0.0 1 1.4 1 0.8 3 2.1 7 0.90
Current treatment typea
No treatmentb 12 9.2 14 9.37 9 6.3 2 2.7 2 1.5 7 4.8 46 5.9
Pharmacotherapy only 71 54.2 84 55.6 33 22.9 45 60.8 48 35.8 93 63.7 374 48.0
BT only 10 7.7 10 6.6 59 41.0 1 1.4 9 6.7 1 0.9 90 11.6
Pharmacotherapy and BT 37 28.5 43 28.5 43 29.9 26 35.1 75 56.0 45 30.8 269 34.5
Current treatment classc, d
Short-acting MPH 39 34.2 56 36.8 43 54.4 25 31.7 0 0.0 16 10.2 179 25.1
Long-acting MPHe 73 64.0 82 54.0 0 0.0 45 57.0 91 68.9 107 68.2 398 55.8
Short-acting AMP 0 0.0 1 0.76 7 8.9 1 1.3 0 0.0 2 1.3 11 1.5
Atomoxetinef 1 0.9 13 8.6 29 36.7 8 10.1 13 9.9 32 20.4 96 13.5
Others 1 0.9 0 0.0 0 0.0 0 0.0 28 21.2 0 0.0 29 4.1
N total number of patients, BT behavioural therapy, MPH methylphenidate, AMP amphetamine
a Percentages are based on the total number of patients reporting treatment type
b Not included in any analyses
c Percentages are based on the total number of patients reporting treatment class
d Treatment could be monotherapy or combination therapy
e Long-acting MPH is not approved for use in Italy
f Atomoxetine is not approved for use in France
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Generally, we found positive associations between the
need to improve inattention as a treatment goal at diagnosis,
increased patient engagement and increased family involve-
ment and all three outcomes (adherence, symptom control
and physician satisfaction with treatment). The odds of a
favourable outcome for patients with improving inattention
as a treatment goal were approximately twofold higher than
for those patients for whom improving inattention was not a
stated goal (OR=2.1; 95 % CI=1.5–3.1; p<0.0001; Table 4).
Similarly, improved mean scores for patient engagement
and family involvement were positively associated with
adherence, symptom control and physician satisfaction.
For example, adherent patients had a mean engagement
score of 6.7 versus 5.7 for nonadherent patients (Table 4).
Alternatively, increased comorbidities at diagnosis (both
total number and specific types) were negatively associated
with outcomes. For instance, in patients with comorbid
Tourette syndrome, the odds of favourable symptom control
and physician satisfaction were reduced fivefold (OR=0.2;
95 % CI=0.1–0.5; p<0.0001) and 3.3-fold (OR=0.3; 95 %
CI=0.1–0.6; 0.0001≤p<0.001), respectively. Patients per-
ceived to have complete symptom control had a mean
number of 2.2 comorbidities compared to a mean number
of 3.0 comorbidities in those patients without complete
symptom control (p<0.0001; Table 4).
The presence of certain ADHD symptoms at the time of
diagnosis was also associated with unfavourable outcomes.
The odds of favourable physician satisfaction with ADHD
treatment was reduced 1.7-fold in patients with the symptom
of anger at the time of diagnosis (OR=0.6; 95 % CI=0.4–
0.8; 0.0001≤p<0.001). Furthermore, as seen in Table 4,
there were multiple impairments at the time of diagnosis
that were negatively associated with adherence, symptom
control and physician satisfaction. For example, patients
whose symptoms were completely controlled demonstrated
a mean ‘active defiance’ impairment score of 5.6 compared
with a score of 6.5 in those who did not demonstrate com-
plete symptom control (p<0.0001).
Country differences
Patient comorbidities at the time of ADHD diagnosis varied
considerably across countries. The majority of countries
reported at least one patient with each comorbidity repre-
sented in Fig. 2; however, data from Germany did not include
any patients with schizophrenia, obsessive compulsive disor-
der, alcohol abuse, epilepsy or drug abuse; the Netherlands
did not report any patients with bipolar disorder, schizophre-
nia or alcohol abuse; and Spain and the UK did not report any
patients with schizophrenia. Also, patient membership to pri-
vate insurance differed based on country. One hundred percent
of patients from the Netherlands had private insurance com-
pared with just 2.7 % of patients from the UK.
The diagnostic criteria used by the treating physicians
varied based on country. The DSM-IV criteria for diagnosing
ADHD were most commonly used in France (69.2 %
[90/130]), Italy (70.1 % [101/144]), the Netherlands
(81.1 % [60/74]) and Spain (79.1 % [106/134]). ADHD Con-
nors Test was frequently part of the diagnostic assessment in
the UK (69.2 % [101/146]). ICD-9/ICD-10 diagnostic criteria
were most commonly used in Germany (87.4 % [132/151]).
Country level variation in the treatment of ADHDwas also
noted. The UK had the highest rate of treatment with pharma-
cotherapy alone at 63.7 % (93/146). Treatment with BT alone
was most common in Italy (41 % [59/144]) and least common
in the UK (<1 % [1/146]). More than 54 % of patients in Italy
used short-acting methylphenidates, while Spain did not re-
port any use at all. Atomoxetine was most commonly used in
Italy (36.7 %), but it was not available in France because it has
not been approved by the Comité Economique des Produits de
Santé. Short-acting amphetamines were not used in France or
Spain and were used by less than 2 % of patients in Germany,
the UK and the Netherlands. The highest use for short-acting
amphetamines is in Italy (9 %) (Table 3).
The percentage of patients who adhered to their ADHD
treatment ranged from 50.8 % (62/122) in Italy to 80.3 %
(94/117) in France. Physicians from the Netherlands reported
the highest percentages of ‘complete symptom control’
(52.8 % [38/72]), while Italian physicians reported the lowest
percentage (16.4 % [22/134]). Methylphenidate ‘very good
responders’ ranged from 11.1 % (16/144) in Italy to 35.1 %
(53/151) in Germany. Physicians in Germany (46.0 %
[63/137]) and the Netherlands (59.7 % [43/72]) reported the
highest percentages of ‘very satisfied’, while physicians in
Italy reported the lowest percentage (14.8 % [20/135]).
Discussion
Country-level variations were evident in patient characteris-
tics as well as ADHD diagnosis, treatment and outcomes.
Patients had differences in comorbidities at the time of ADHD
diagnosis across countries. Therefore, it is important that all
treating physicians have a similar knowledge and understand-
ing not only of the diagnosis and management of ADHD but
also the associated comorbid conditions to deliver optimal
treatment based on individual patient needs and a global view
of the problems. Evaluations of differences in treatment based
on patient comorbidities are planned for future analyses.
Patients also had differences in private insurance member-
ship based on country. In the Netherlands, all patients were
members of private insurance, but in the UK, where ADHD
treatment is free under the National Health Service, only 2.7%
had private insurance. The discrepancies in membership to
private insurance across countries may influence ADHDman-
agement and treatment decisions for patients. Future analyses
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are planned to better understand ADHD management differ-
ences within countries and specialties as well as differences in
treatment based on comorbidities.
Within each country, the criteria used to diagnose ADHD
varied by physician specialty as well. The criteria provided
in DSM-IV were the most commonly used to diagnose
ADHD in the countries studied. Use of the Swanson, Nolan
and Pelham IV Rating Scale (SNAP) and the Inattention/
Overactivity With Aggression (IOWA) screening tool in-
creased each year from 2004 to 2007. Although scales like
SNAP and IOWA are valuable for screening patients for
ADHD, if used alone, they may lead to overdiagnosis or
misdiagnosis. Adoption of standardized diagnostic criteria
across countries may address some of the variability noted
worldwide in ADHD prevalence [15, 19]. ADHD diagnosis
and management differences within countries and within
physician specialties are planned for future analyses.
At ADHD diagnosis, physicians regarded core ADHD
symptom control as a primary therapeutic goal. In the short
term, controlling core symptoms is of key importance as
hyperactivity, impulsivity and inattention frequently create
dysfunction for patients, their families and their peers. How-
ever, it is important to note that ADHD treatment is not
limited to symptom control only. Treatment goals must also
include longer-term objectives such as improving the quality
of life for both the patient and their families and reducing
functional impairment for the patient [18].
In this study of ADHD treatment in European countries,
more than half of patients received long-acting methylpheni-
date as the treatment of choice, except in Italy where it was not
approved and therefore short-acting methylphenidates were
the treatment of choice. This may also account for a higher
rate of BT only and a lower rate of treatment response and
treatment satisfaction in Italy compared with other countries.
Whether or not BTwas available through national health plans
and consideration of waiting times may have affected these
numbers. In addition, differing recommendations from the
various physician specialties and other variations in availabil-
ity of medication may have also influenced these data. The
rationale behind the choices of ADHD treatments (i.e. symp-
tom severity, comorbidity, etc.) is planned for further analysis.
Overall, across all of the countries studied, patients with
ADHD were considered by physicians to have high rates of
adherence (>80 % weekdays, >50 % weekends) with treat-
ment on school or working days. However, less than one third
of the patients were perceived by their physicians to exhibit
‘complete symptom control’ and less than one third of physi-
cians were ‘very satisfied’ with the current ADHD treatment
for their patients. The low overall percentages and high coun-
try variability for ‘complete symptom control’ and ‘very sat-
isfied’ may be indicative of cultural differences among
countries in the acceptability of physicians indicating dissat-
isfaction with ADHD therapy or as a result of inconsistency
among countries in shared decision-making between physi-
cians and patients/caregivers. We observed that patient/family
involvement in the disorder and its treatment was positively
associated with adherence, symptom control and physician
satisfaction with treatment, reflecting the influence on treat-
ment outcomes of shared decision-making [25]. In addition,
low symptom control and satisfaction may be influenced by
the lack of optimal treatment. In this study, whether or not
titration of medication was optimal was not possible to ascer-
tain. Clearly, physicians should endeavour to optimize man-
agement with pharmacological and nonpharmacological
treatments currently available. Treatment should be individu-
alized for each patient to ensure optimal response. However,
this lack of symptom control and physician satisfaction with
currently available treatment suggests that there also remains
an unmet need in the six European countries studied with
regard to available ADHD treatment options. Patients may
be partial responders or nonresponders to one medication for
ADHD, but that is not predictive of response to another class
of medications [17, 18, 20]. Therefore, treatment optimization
may include consideration of other ADHDmedication classes
not discussed herein, such as long-acting amphetamines [6,
26], alpha-2 agonists [7, 11, 16, 21] or ongoing BT. Manage-
ment of coexisting conditions is also vital to improve overall
outcomes, which was not possible to assess in this study.
Limitations
This study was a retrospective chart review with inherent
study design limitations, including the potential for incom-
plete or missing documentation as well as the inability to
establish causality. The potential for selection bias in this
study should be considered due to the convenience sampling
strategy implemented. It is not known whether a greater
number of physicians participated from secondary referral
centres compared with those from primary care settings; thus,
it is not possible to determine whether an oversampling of
charts frommore complex or difficult patients occurred in this
study. Confounding factors included the variable availability
of ADHD treatments, including BT, across countries and the
lack of information regarding whether a patient started initial
ADHD therapy in a clinic that was different from the clinic
where the actual medical record abstraction occurred. Because
this was an observational study of a convenience sample
where patient charts were not sampled randomly, the general-
izability of these study results to the entire European popula-
tion may be limited. Furthermore, this study was conducted
for descriptive and exploratory purposes and was not
designed for testing of particular statistical hypotheses. As
such, p-values presented in the results should be considered
descriptive. However, given the fact that this is the first
work that attempted to study real-world practice variation
and management of ADHD across European countries, the
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evidence generated in this research still provides valuable
additional information to the body of literature in ADHD.
Conclusions
ADHD management differs across European countries and
across physician specialties. Variations in patient character-
istics as well as ADHD diagnosis, treatment and outcomes
were evident between countries. Although a high proportion
of patients were reported to be adherent to currently available
therapy in Europe, less than one third of physicians perceived
patients as having complete ADHD symptom control and less
than one third of physicians were satisfied with ADHD treat-
ments for their patients. These results suggest that European
patients may benefit from better standardization of ADHD
management across countries and additional treatment options.
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Appendix
Web-based chart abstraction form: key questions
Which of the following statements best describes the
level of compliance of this patient with this treatment for
each specific circumstance?




















less than 25 % of the time
4 4 4
Not applicable / the treatment
is not prescribed for this
circumstance
5 5 5
Don’t know 99 99 99
How well controlled are ADHD symptoms for this





Not controlled at all 4
Don’t know 99
How would you define your level of overall satisfaction
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